During the last session, Halozyme Therapeutics Inc. (NASDAQ:HALO)’s traded shares were 0.53 million, with the beta value of the company hitting 1.43. At the end of the trading day, the stock’s price was $42.22, reflecting an intraday loss of -1.38% or -$0.59. The 52-week high for the HALO share is $56.40, that puts it down -33.59 from that peak though still a striking 40.38% gain since the share price plummeted to a 52-week low of $25.17. The company’s market capitalization is $5.76B, and the average intraday trading volume over the past 10 days was 0.8 million shares, and the average trade volume was 813.26K shares over the past three months.
Halozyme Therapeutics Inc. (HALO) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.20. HALO has a Sell rating from 1 analyst(s) out of 13 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.41.
Halozyme Therapeutics Inc. (NASDAQ:HALO) trade information
Halozyme Therapeutics Inc. (HALO) registered a -1.38% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.38% in intraday trading to $42.22 this Friday, 09/03/21, hitting a weekly high. The stock’s 5-day price performance is 0.50%, and it has moved by 4.45% in 30 days. Based on these gigs, the overall price performance for the year is 53.33%. The short interest in Halozyme Therapeutics Inc. (NASDAQ:HALO) is 6.47 million shares and it means that shorts have 6.17 day(s) to cover.
The consensus price target of analysts on Wall Street is $50.17, which implies an increase of 15.85% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $17.00 and $66.00 respectively. As a result, HALO is trading at a discount of -56.32% off the target high and 59.73% off the low.
Halozyme Therapeutics Inc. (HALO) estimates and forecasts
Statistics show that Halozyme Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Halozyme Therapeutics Inc. (HALO) shares have gone up 6.86% during the last six months, with a year-to-date growth rate more than the industry average at 83.52% against 7.70. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 115.80% this quarter and then jump 68.00% in the quarter after that. In the rating firms’ projections, revenue will increase 64.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $104.04 million as predicted by 11 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $106.96 million by the end of Sep 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $66.68 million and $65.32 million respectively. In this case, analysts expect current quarter sales to grow by 56.00% and then jump by 63.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 41.10%. While earnings are projected to return 282.30% in 2021, the next five years will return 19.00% per annum.
Halozyme Therapeutics Inc. is due to release its next quarterly earnings between November 01 and November 05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Halozyme Therapeutics Inc. (NASDAQ:HALO)’s Major holders
Halozyme Therapeutics Inc. insiders own 1.03% of total outstanding shares while institutional holders control 95.68%, with the float percentage being 96.68%. Blackrock Inc. is the largest shareholder of the company, while 459 institutions own stock in it. As of Mar 30, 2021, the company held over 18.44 million shares (or 12.95% of all shares), a total value of $768.66 million in shares.
The next largest institutional holding, with 13.26 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 9.31% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $552.72 million.
Also, the Mutual Funds coming in first place with the largest holdings of Halozyme Therapeutics Inc. (HALO) shares are Artisan Small Cap Fund and Vanguard Total Stock Market Index Fund. Data provided on Mar 30, 2021 indicates that Artisan Small Cap Fund owns about 4.99 million shares. This amounts to just over 3.50 percent of the company’s overall shares, with a $207.9 million market value. The same data shows that the other fund manager holds slightly less at 3.82 million, or about 2.68% of the stock, which is worth about $159.33 million.